Navigation Links
CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology
Date:5/26/2009

animal models.

The concept behind the L.E.A.P.S. technology is to directly mimic cell/cell interactions on the dendritic and T-cell surface with synthetic peptides. The L.E.A.P.S. constructs containing the antigenic disease epitope linked to an Immune/T-cell binding ligand (I/TCBL) can be manufactured by peptide synthesis or by covalently linking the two peptides. Depending upon the type of L.E.A.P.S. construct and I/TCBL used, CEL-SCI is able to direct the outcome of the immune response towards the development of T-cell function with primarily effector T-cell functions (T Lymphocyte; helper/effector T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). The L.E.A.P.S. vaccine constructs are chimeric peptides which combine antigen specificity with immune response modulation.

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine which is being readied for a global Phase III trial. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
2. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
3. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
4. CEL-SCI Corporation Announces 2008 Financial Results
5. CEL-SCI Corporation Releases Letter to Shareholders
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. CEL-SCI Takes Delivery of New Manufacturing Facility
8. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
9. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
10. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
11. CEL-SCI to Present at the Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , ... August 05, 2015 , ... ... the “Product Handbook – the complete product line.” The handbook provides a ... “This new product handbook consolidates our complete standard product offering into an easy-to-navigate ...
(Date:8/4/2015)... Inc. (NYSE: BIOA ), a leader in renewable ... ending June 30, 2015. Highlights included: , The Sarnia ... The final cost of the Sarnia plant is projected ... high end of the estimate communicated at the onset ... The company announced commercial collaborations in two targeted industry ...
(Date:8/4/2015)... ... August 04, 2015 , ... Graphite Metallizing Corporation, ... equipment, announces the appointment of Dennis Rawle as European Director of Sales. Rawle ... recently, he was General Manager and Technical Sales Manager for pump products at ...
(Date:8/4/2015)... PORTLAND, Oregon , August 4, 2015 /PRNewswire/ ... published by Allied Market Research, titled, "World Cardiac ... global cardiac biomarker market would generate the revenue ... of 18.9% from 2015 to 2020. Cardiac Troponins ... throughout the forecast period due to high sensitivity ...
Breaking Biology Technology:Spirax Sarco releases Product Handbook 2BioAmber Reports Second Quarter 2015 Financial Results 2BioAmber Reports Second Quarter 2015 Financial Results 3BioAmber Reports Second Quarter 2015 Financial Results 4BioAmber Reports Second Quarter 2015 Financial Results 5BioAmber Reports Second Quarter 2015 Financial Results 6BioAmber Reports Second Quarter 2015 Financial Results 7BioAmber Reports Second Quarter 2015 Financial Results 8BioAmber Reports Second Quarter 2015 Financial Results 9BioAmber Reports Second Quarter 2015 Financial Results 10BioAmber Reports Second Quarter 2015 Financial Results 11BioAmber Reports Second Quarter 2015 Financial Results 12Dennis Rawle Joins Graphite Metallizing Corporation 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 3Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 4Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 5
... Amerigroup Corporation (NYSE: ... program in Texas designed to build upon its already successful ... Health® to provide automated statewide obstetrics (OB) assessments to screen ... maternity program in the Dallas and Fort Worth areas. ...
... October 7, 2011 In support of Breast ... frame purchased in October. There are over 50 styles to ... To view the full range of pink glasses please visit ... Cancer Awareness: For women in the UK breast ...
... 6, 2011 AlloSource, ( www.allosource.org ) ... soft-tissue allografts for use in surgical procedures around the ... by the Denver Business Journal,s inaugural awards ... costs and diminishing employee benefits, the Denver Business ...
Cached Biology Technology:Amerigroup Enhances Maternal Outreach Efforts 2Amerigroup Enhances Maternal Outreach Efforts 3Buy Pink Glasses From LensWay and £20 Will be Donated to Breast Cancer Research 2AlloSource Named One of Denver's Healthiest Employers 2AlloSource Named One of Denver's Healthiest Employers 3
(Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
(Date:7/8/2015)... , N.J. and NEW YORK , ... and Guidepoint today announced BD & ... healthcare companies with free access to Guidepoint,s expert network ... start-ups that are developing cutting-edge technologies to improve healthcare ... dedicated Guidepoint research manager, each start-up entrepreneur will be ...
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... of patients who required care at Duke University Hospital during ... been vaccinated had severe cases and needed the most intensive ... patients treated for flu at the academic medical center from ... that only two of the 22 patients who required intensive ...
... Bethesda, MD FASEB MARC (Maximizing Access to Research ... the Association of Biomolecular Resource Facililties (ABRF) annual meeting ... are meant to promote the entry of students, postdoctorates ... of the basic science community and to encourage the ...
... Research Careers) Program has announced the travel award recipients ... Regional Chapter meeting in Fort Worth, TX from February ... entry of students, postdoctorates and scientists from under represented ... and to encourage the participation of young scientists at ...
Cached Biology News:Young, unvaccinated adults account for severest flu cases 2
... for all tested applications). ... from within residues 1 - 100 of Mouse ... proprietary) (Peptide available as ... 5453 Swiss Protein ID: ...
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
...
Biology Products: